SEHK:2616Biotechs
Evaluating CStone Pharmaceuticals (SEHK:2616) After ESMO Category I A Backing For Sugemalimab
Sugemalimab’s new Category I, A recommendation in European Society for Medical Oncology guidance for early and locally advanced non small cell lung cancer puts CStone Pharmaceuticals (SEHK:2616) firmly in focus for investors tracking oncology developments.
See our latest analysis for CStone Pharmaceuticals.
The ESMO endorsement arrives alongside strong recent trading, with the HK$10.07 share price supported by a 30 day share price return of 38.32% and a 1 year total shareholder return above...